Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 5/20 | 0.66 |
| ▸ | TERT | O14746 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6602282 | 0.82 | NQO2 (0.61) | NQO2TERTPOLBKDM4ELMNA | |
| SCHEMBL6615983 | 0.81 | TERT (0.59) | NQO2TERTPOLBKDM4ELMNA | |
| SCHEMBL24003950 | 0.79 | TERT (0.57) | NQO2TERTPOLBKDM4EL3MBTL1 | |
| SCHEMBL6846673 | 0.78 | CYP1A2 (0.57) | NQO2TERTPOLBKDM4ELMNA | |
| SCHEMBL3235863 | 0.78 | NCF1 (0.63) | NQO2TERTPOLBKDM4ELMNA | |
| SCHEMBL6613348 | 0.77 | NQO2 (0.75) | NQO2POLBKDM4ENCF1RAD52 | |
| SCHEMBL6617291 | 0.77 | NQO2 (0.67) | NQO2POLBKDM4ENCF1ALDH1A1 | |
| SCHEMBL23999412 | 0.77 | TERT (0.55) | NQO2TERTPOLBKDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL30579056 | 0.77 | NCF1 (0.61) | NQO2TERTPOLBKDM4ELMNA | |
| SCHEMBL1238925 | 0.77 | CYP1A2 (0.60) | TERTPOLBLMNAL3MBTL1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060030565-A1 | Amide derivatives and nociceptin antagonists | JAPAN TOBACCO INC. | 2006-02-09 | — | — | US | disclosed |
| US-6903094-B2 | Amide derivatives and nociceptin antagonists | JAPAN TABACCO, INC. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20040053966-A1 | Chemical derivatives and their application as antitelomerase agent | AVENTIS PHARMS S.A. | 2004-03-18 | — | — | US | disclosed |
| EP-1373252-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-01-02 | — | — | EP | disclosed |
| US-6645964-B1 | 1,3,5-Triazine compounds substituted with aromatic N-heterocycle; anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2003-11-11 | — | — | US | disclosed |
| EP-1244650-B1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA SA (FR) | 2003-06-25 | — | — | EP | disclosed |
| US-20030055087-A1 | Amide derivatives and nociceptin antagonists | JAPAN TOBACCO INC. | 2003-03-20 | — | — | US | disclosed |
| CN-1402722-A | Arylamine derivatives and their use as anti-telomerase agents | AVENTIS PHARMA SA (FR) | 2003-03-12 | — | — | CN | disclosed |
| WO-2002076975-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | WO | disclosed |
| EP-1244650-A1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2002-10-02 | — | — | EP | disclosed |
| US-6410561-B1 | ANALGESICS | JAPAN TOBACCO INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| WO-2001040218-A1 | ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2001-06-07 | — | — | WO | disclosed |
| EP-1072263-A1 | AMIDE DERIVATIVES AND NOCICEPTIN ANTAGONISTS | JAPAN TOBACCO INC. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055087-A1 | Amide derivatives and nociceptin antagonists | OPRL1, OPRD1, OPRK1 | NQO2 752/4885TERT 3158/4885POLB 3841/4885 |
| US-20040053966-A1 | Chemical derivatives and their application as antitelomerase agent | NTPCR, DPYD, NME1 | NQO2 101/4885TERT 168/4885POLB 344/4885 |
| US-20060030565-A1 | Amide derivatives and nociceptin antagonists | OPRL1, OPRD1, OPRM1 | NQO2 464/4885TERT 2806/4885POLB 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.